You are here: Industry Insights > Volition

News List

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring prnewswire
July 23, 2021
VolitionRx Limited (NYSE AMERICAN: VNRX) cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with researchers at two leading NHS Foundation Trusts on two studies in COVID-19.
VolitionRx Limited Opens its New Manufacturing Facility in Belgium prnasia
January 26, 2021
VolitionRx Limited announced the opening of "Silver One", its 10,000 square foot dedicated manufacturing facility located on the same science park as its Research and Development laboratory in Isnes, Belgium.
Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test July 14,2020
July 14, 2020
Cameron Reynolds, Chief Executive Officer of Volition commented, "Nu.QTM has shown correlation with more severe COVID-19 cases implying strong prognostic potential, and we are now focused on the completion of larger longitudinal studies that would be need
Volition Develops a New Improved Nu.Q™ Assay Format prnasia
January 15, 2020
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format.
Volition Appoints Dr. Phillip Barnes to Board of Directors En-CPhI.CN
October 11, 2019
VolitionRx Limited announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effective October 9, 2019.
Volition Granted Four Additional Patents prnasia
September 15, 2017
Dr. Jake Micallef, Chief Scientific Officer of Volition, commented, "Our worldwide portfolio of granted patents that protects various aspects of Volition's Nu.QTM technology is growing.